image (1)

CanaQuest Overview

Comprehensive solution for epilepsy drug commercialization and a platform for future neurological treatments

CanaQuest Corp is a pre-clinical-stage life sciences company positioned to become the next “GW Pharma 2.0.”

  • Mission: Next-generation targeted endocannabinoid therapeutics for neurological disorders with improved safety and efficacy.
  • Mechanism of action: Leverage the power of PPARɣ agonist pathway to administer cannabidiol in proprietary formulation for enhanced brain penetration.
  • Platform: Novel natural drug product derived from cannabidiol + proprietary formulation.
  • Current status: Completed preclinical in-vivo studies using CQ-001.
  • Strategy: Best-in-class, fast-to-market strategy leveraging Epidiolex patient safety data to conduct bioequivalence (BE) study followed by Phase IIb/III study for NDA submission.